QSI Quantum-Si incorporated Potential ReentryIf you haven`t bought the Double Bottom on QSI:
Then it seems that there is a potential reversal from this level.
Earnings were a beat, but too small to justify the recent breakout.
The Elliot Waves chart pattern indicates a price target of $2.93.
Looking forward to read your opinion about it!
GENE
QSI Quantum-Si Earnings Release on Monday, Before the BellIf you haven`t bought the Double Bottom:
Then you should know that QSI, Quantum-Si incorporated, also known as The Protein Sequencing Company is bringing single-molecule protein sequencing to every lab, everywhere, enabling new discoveries that will transform the world we live in.
Importance of Protein Sequencing:
- Understanding Cellular Processes: Proteins are involved in virtually every cellular process, and their sequencing is vital for understanding how these processes are regulated and how dysfunction leads to diseases.
- Drug Development: Protein sequencing assists in drug discovery by identifying specific targets for pharmaceutical intervention. This knowledge enables the design of drugs that can interact with specific proteins, thereby treating diseases more effectively.
- Bioengineering and Enzyme Production: Protein sequencing is critical in the field of bioengineering, allowing the design of proteins with tailored functions for various applications, including industrial enzyme production and bioremediation.
I think protein sequencing should have the same importance as gene sequencing.
Gene sequencing has revolutionized medical research, agriculture, and our comprehension of evolutionary history. On the other hand, protein sequencing has paved the way for targeted drug development, bioengineering, and the investigation of cellular processes.
QSI has cash and cash equivalents of $322.1 million as of March 31,2023 to provide a runway to support operations and invest in the business into 2026, and NO debt!
This Quarter started he sale of PlatinumTM instruments and kits with a gross margin of 48.8%.
QSI has a Market Cap of $485Mil vs CRSP, my favorite gene editing company, with a Market Cap of 4.046Bil.
So there is still a lot of upside in QSI Quantum-Si incorporated!
Looking forward to read your opinion about it.
Gene - Hiden gem target 180$What Is Genopets?
Genopets is the world's first Free-to-Play, Move-to-Earn NFT game on Solana that makes it fun and rewarding to live an active lifestyle. Genopets combines user's step data from their mobile device with blockchain Play-to-Earn economics so players can earn crypto for taking action in real life as they explore the Genoverse evolving and battling their Genopet.
Genopets merges the nurture and evolution of Tamagotchi, the training and battling of Pokemon, and the fitness and social incentives of Strava while rewarding players with crypto for staying active in their daily lives. Genopets has coined this, "Move-to-Earn".
What is the GENE Token?
GENE Token is a governance and staking token that represents the value of the Genopets game as a whole and is used to craft in-game NFTs. GENE holders gain access to exclusive peaks at new content, have a voice in-game design, and can participate in special community perks like airdrops.
BNTC Gene Therapy Penny Stock at All Time LowBNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference based therapeutics.
BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it.
On 2/17/2022 P. Trucchio from HC Wainwright brokerage Initiated Coverage for BNTC with a Buy rating and a price target of $10.00.
The price of the stock can easily double in my opinion.
AVRO 1330% upside potential according to this analyst!!!AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have the largest stakes in the company with an average around $9 per share.
On 1/5/2022 Barclays brokerage Boosted the Price Target of AVRO from $6.00 to $22.00.
The stock is now at all time low: $1.65.
the MARKET CAP is only 71.978Mil
I think it can be an easy buyout at this point.
What are we waiting for?
BNTC Gene Therapy Penny StockBTC Benitec Biopharma is sitting now at a key support from which we can expect a bounce.
We know that earlier this year they had a 7.5mil offering price to the public of $4.25 per share and that Morgan Stanley has a 5.2% stake in the genetic drug company.
Benitec's "proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration.
Market Cap 22.472Mil
My price targets are 4.70 and 5.70 usd.
CRSP CRISPR Therapeutics at 52 Week LowCRSP CRISPR Therapeutics 52 Week Range 77.42 - 220.20
Now the price is 80.08usd.
Bounced from its last support level.
Barclays has a price target o 148usd for it.
My price target by Q1 2022 is the 100usd resistance.
Looking forward to read your opinion about it.
BNTC Benitech Biopharma we bought the dipMorgan Stanley disclosed in an SEC filing that it had increased its stake in the company by around 5.2%!
Don`t worry, it has still upside potential, despite the 130% increase in the Pre-Market.
Market Cap of only 15.37M
This is a 5X stock, Not trading advice as you know! :)
This was a private call from my trading group and one of my top picks for March.
You can check the transcripts here:
www.patreon.com
If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
Crispr - DNA/Gene editing Technical Analysis
Since early December, we have had over a dozen tails on the purple up-trend arrow drawn in.
The 50sma is now coming into play, as a break below that, could take us another 20% down to the 100sma.
An appropriate level to exit the trade then, would be below the 50sma.
There also horizontal support as we fill the gap.
Important Note:
Earnings are on February 10th; so be aware of this if you plan to enter the trade.
Opinion
I believe this company is the future of gene editing.
Check out a documentary of the company on Netflix called Human Nature.
*It is more about how Crispr (DNA modification) works, than how the company makes money.
Enjoy your weekend,
dorfmaester
And just like that, Sangamo $SGMO is back at ATH market capSangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation.
GENE on bottom channel.. Make or break next 24 hoursNASDAQ:GENE is a great value play here.. TIGHT TIGHT $0.15-$0.20 stop loss while it is sitting on the bottom of the channel it has been trading in... with upside of 15:1 profit to risk ratio. I don't look for the upper channel to hit but the midline is a possibility. The next 24 hours will either hit your stop loss or give you a fat profit. :) GO LONG!
BLCM #VolatilityWatchBLCM has been in continuous long-term downtrend since IPO. Stock price has been showing signs of a bo...
Click here to read the rest of my analysis on BLCM.
Disclosure: I am long BLCM. This is not a recommendation to buy/sell as I am NOT a financial advisor. Please do your homework before investing.